Proposals accepted until March 31.
SLAS Discovery Guest Editors M. Paola Castaldi, Ph.D. (Director, Head of Chemical Biology, AstraZeneca) and Stewart L. Fisher, Ph.D. (Chief Scientific Officer, C4 Therapeutics, Inc.) invite the submission of abstracts pertaining to protein degradation for publication in a 2021 Special Issue. Manuscript proposals (abstracts) will be used to select and invite papers for review and publication consideration.
Drs. Castaldi and Fisher seek high-quality, short- or full-length research reports, reviews, and perspectives related to targeted protein degradation. Submissions covering the range of protein degradation modalities - heterobifunctional (PROTACs), “molecular glues” and ligand-induced degradation - or the scientific approaches required to identify, characterize or optimize these therapeutic agents are welcomed. Manuscript proposals (abstracts) are encouraged from academia, industry, and vendors. Areas of particular interest include, but are not limited to:
Submit your manuscript proposal before March 31, 2020. It should include your name, contact information, affiliation, a working title, and abstract (250-500 words) as an MS Word document.
Invited manuscripts will need to be completed and submitted by August 1, 2020. All submitted papers will be subject to peer-review to ensure scientific rigor, clarity of expression and integration with other contributions in the SLAS Discovery special issue.
Questions? Please e-mail email@example.com or call +1.630.256.7527, ext. 106.